Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant to Develop Dementia Diagnosis Products

13 Dec 2013 07:00

RNS Number : 4517V
IXICO plc
13 December 2013
 



 

IXICO Awarded Technology Strategy Board Grant to Support the Development of Dementia Diagnosis Products

 

13 December 2013, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a Stratified Medicine Grant by the UK's innovation agency, the Technology Strategy Board to provide funding to support the development of products to address the global dementia challenge.

 

The grant has been awarded under the Technology Strategy Board's recently launched 'Advancing In-Vivo Imaging for Stratified Medicine' competition. 

 

For this project, a consortium led by IXICO, which includes Imperial College, London as a research partner, Medimmune Limited (the global biologics research and development arm of AstraZeneca) and a second leading global pharmaceutical company as commercial partners, will apply a machine learning framework to a unique combination of reference data to develop a digital dementia prognosis tool. This will use commonly collected diagnostic information (including MRI scans and cognitive, functional and demographic data) to stratify patients based on their expected rate of decline. This could help with the diagnosis of dementia in the clinic and also with the enrichment of patient populations enrolled in clinical trials of investigational drugs, potentially improving the likelihood of measuring a therapeutic effect.

 

Several further global pharmaceutical companies have expressed interest joining the project as collaborators, and contributing clinical trial data in due course. The total value of the 24 month research project is approximately £1 million. The value of the grant is £633,962 of which £456,956 is allocated to IXICO and the remainder to Imperial College. The pharmaceutical partners and collaborators are contributing scientific resources from their R&D teams and access to data from completed clinical trials.

 

This brings the total grant funding secured by IXICO in the last 18 months to approximately £2.6 million of which approximately £2.4 million remains to be drawn down by IXICO.

 

This week the Technology Strategy Board features IXICO, the "Dementia Champions", as its Success Story www.innovateuk.org/success-stories detailing a funding story that stretches back 5 years.

 

Professor Derek Hill, Chief Executive of IXICO commented: "We are pleased to have been awarded this Technology Strategy Board grant. IXICO's products and services are focused on three overlapping areas within clinical trials, experimental medicine and diagnostics; the scope of this project will benefit our work in each. We look forward to working with Imperial and our commercial collaborators to develop important tools with the potential to improve clinical diagnosis of dementia and accelerate the development of effective treatments for Alzheimer's disease."

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

 

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

 

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMZZZRGFZZ
Date   Source Headline
11th Jan 20123:53 pmRNSBlocklisting Interim Cancellation
3rd Jan 201212:00 pmRNSBlocklisting Interim Review
28th Nov 201110:09 amRNSDirector/PDMR Shareholding
28th Nov 201110:08 amRNSDirector/PDMR Shareholding
24th Nov 20117:00 amRNSFinal Results
7th Nov 20118:51 amRNSBlocklisting Interim Review
4th Oct 20117:00 amRNSResearch Update
29th Sep 20117:00 amRNSResearch Update
16th Aug 20117:00 amRNSInterim Management Statement
28th Jul 20117:31 amRNSResearch Update
12th Jul 201112:04 pmRNSBlocklisting Interim Review
5th Jul 201112:04 pmRNSTotal Voting Rights
17th Jun 20113:28 pmRNSBlocklisting Interim Review
26th May 20117:00 amRNSHalf Yearly Report
17th May 20118:35 amRNSNotice of Results
5th May 20117:00 amRNSBlocklisting Interim Review
31st Mar 20119:07 amRNSResult of AGM
2nd Mar 201112:27 pmRNSHolding(s) in Company
15th Feb 20117:00 amRNSInterim Management Statement
7th Feb 201112:18 pmRNSAnnual Information Update
1st Feb 20118:54 amRNSTotal Voting Rights
1st Feb 20118:53 amRNSAnnual Financial Report & Notice of AGM
19th Jan 20112:14 pmRNSDirector/PDMR Shareholding
19th Jan 20112:14 pmRNSDirector/PDMR Shareholding
14th Jan 201110:18 amRNSHolding(s) in Company
10th Jan 201111:45 amRNSHolding(s) in Company
7th Jan 20111:50 pmRNSBlock Listing Application
7th Jan 201110:59 amRNSBlocklisting Application
4th Jan 20112:01 pmRNSTotal Voting Rights
21st Dec 201012:19 pmRNSDirector/PDMR Shareholding
21st Dec 201012:18 pmRNSDirector/PDMR Shareholding
14th Dec 20101:15 pmRNSBlock Listing Application
30th Nov 20107:00 amRNSFinal Results
17th Nov 201011:44 amRNSResearch Update
3rd Nov 20109:29 amRNSBlocklisting Interim Review
1st Nov 20104:31 pmRNSPreliminary Results - Change of Date
1st Nov 201010:41 amRNSNotice of Results
29th Sep 20102:00 pmRNSPresents Cogane data at scientific conferences
18th Aug 20107:00 amRNSInterim Management Statement
22nd Jul 20101:49 pmRNSDirector/PDMR Shareholding
22nd Jul 20101:49 pmRNSDirector/PDMR Shareholding
5th Jul 201010:59 amRNSChange of Registered Office
21st Jun 20107:00 amRNSAppointment of Chief Executive Officer
14th Jun 20107:00 amRNSRegulatory Approval to Begin Cogane PII Trial
24th May 20107:00 amRNSHalf Yearly Report
19th May 20104:25 pmRNSNotice of Results
4th May 20102:13 pmRNSBlocklisting Interim Review
1st Apr 201012:36 pmRNSDirector/PDMR Shareholding
1st Apr 201012:35 pmRNSDirector/PDMR Shareholding
1st Apr 201012:34 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.